Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Saturday, September 11, 2010

A Friend of Mine, just tested positive on (3) perspectives for CCSVI - Now what ?

Ok everybody - A friend of mine has questions.
As per the CCSVI doppler scan shown below, he was told that he tested positive for CCSVI.
So, he told me that he wants to go to Costa Rica and I mentioned that he will need follow-up care and she not do this procedure anywhere other than in the USA.
- Well then as near to Florida as one can get, where might be the nearest Vascular doctor doing the liberation treatment. Your feedback will help my friend who will check this blog post and what feeds to my facebook page...  Respond please...........


 

MS Views and News, Inc., has partnered with Macy’s nationwide, to save you a few dollars

SHOP for a CAUSE - Find THE MAGIC of Giving Back on Saturday October 16th, 2010.It's Fast and Simple. Purchase a $5.00  Macy's Coupon from 'MS Views and News' and get up to a 20% discount from Macy's on October 16th.  The coupon will also allow you to ENTER FOR A CHANCE TO WIN A $500.00 Gift Card.

MS Views and News, Inc., has partnered with Macy’s nationwide (USA) in a Shop for a Cause event. Macy’s has been sponsoring this event since 2006. 








For only a $5.00 donation to MSV&N you will receive one ticket to be used at any Macy’s department store, anywhere at all.  This coupon entitles you to shop at Macy’s onSaturday, October 16, 2010. 


Shop for a Cause tickets provide discount savings in most departments all day long. Shop for a Cause is special because you can save on most items throughout the store and online. Additionally you will be entered for an opportunity to win a $500 gift card. Your charitable donation to 'MS Views and News' (MSV&N) is tax deductible.

Kindly submit your $5.00 donation plus an additional $0.50 to cover postage and handling, for a total of $5.50, and you will be sent your saving coupon by mail.  All Macy’s tickets will be sent upon receipt of your contribution. 

Please mail your check to: 
MS Views and News, Inc.
8669 SW 51st Street
Cooper City, Fl. 33328-4301

Credit card donations, including Master Card and Visa, will be accepted by email or telephone  Stuart Schlossman at 954-684-1683. Please be sure to provide a mailing address for any coupon which requires mailing. 

Feel free to contact  Jill Molberger (jebmol@aol.com) or the founder and president of MS Views and News, Stuart Schlossman (stuart@msviewsandnews.org) with any questions

Biogen, Glaxo pour millions into Stem Cell Research

Source: BizJournals


Biogen Idec and GlaxoSmithKline are among the companies backing a iPerian Inc., a San Francisco-based company using stem cells for drug discovery.

Biogen Idec New Ventures, part of Weston, Mass.-based Biogen (Nasdaq: BIIB), and SR One, the independent venture are of U.K.-based GSK (NYSE: GSK), were among the investors in iPerian’s $28 million series B equity financing round. Other investors include Kleiner Perkins Caufield & ByersHighland Capital PartnersMPM Capital, Google Ventures, FinTech Global Capital, Mitsubishi UFJ Capital and ATEL Ventures.

iPerian is working to use patient-derived induced pluripotent, or iPSC, stem cells for drug delivery.

“iPierian has industrialized the new science of iPSC technology for drug discovery, and their platform has the potential to transform pharmaceutical discovery and development across a broad range of therapeutic areas,” said Rajeev Dadoo, a partner at SR One who will participate as an observer on the iPierian Board of Directors. “The progress of their lead programs has demonstrated the promise of this approach to identify novel, disease-modifying therapeutics, and we look forward to helping iPierian grow and succeed as the leader in the application of iPSC technology.”

Biogen employs about 850 people at a manufacturing plant in Research Triangle Park, while GSK (NYSE: GSK) maintains its North American headquarters in RTP and employs about 5,000 across the Triangle.

Reporter e-mail: jgallagher@bizjournals.com


Read more: Biogen, Glaxo pour millions into S.F. firm iPerian - Triangle Business Journal 



***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************

Friday, September 10, 2010

Genmab Announces Results of Ofatumumab Phase II Study in Multiple Sclerosis


Genmab A/S  - 10.09.2010 

Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. 



Summary: Genmab announces 48 week results from a Phase II study of ofatumumab in RRMS.                                                                       
Copenhagen, Denmark; September 10, 2010 - Genmab A/S (OMX: GEN) announced today encouraging results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis (RRMS). A total of 38 patients were included in this double-blind, dose escalation trial. 




Patients were randomized to receive two infusions of 100 mg, 300 mg or 700 mg of ofatumumab or placebo. After 24 weeks, the patients randomized to placebo were treated with ofatumumab and patients who were treated with ofatumumab received placebo. All patients were then followed for an additional 24 weeks. 




In the study, there were no dose limiting toxicities, no unexpected safety findings, and no patients tested positive for human anti-human antibodies. Efficacy was assessed by MRI (magnetic resonance imaging) as a secondary endpoint. Repeated MRI scans showed a sustained reduction in the number of brain lesions up to week 48 in patients (n=26) who were treated with ofatumumab followed by placebo. Patients who received placebo followed by ofatumumab (n=12) showed similar 24 week results to those who were treated with ofatumumab followed by placebo. 





READ MORE



***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************

LDN Research Study for Multiple Sclerosis

If you have MS and ANY of the following descriptions applies to you, we would be grateful if you could spare a few minutes of your time to take part in this survey: -
  • you are currently taking LDN, and have been doing so for at least four months
  • you have taken LDN in the past but are no longer taking it
  • you took part in our first survey
In addition, we hope that all participants will be willing to complete this survey every six months, enabling us to effectively track the progress of a large number of LDN users.
The survey results will be presented to the medical profession, research and funding bodies, posted on the internet and printed wherever possible.
Please note - all personal details are kept private and confidential. Survey participants will remain anonymous in all presentations of the survey results.

Click here to access the survey area





***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************

Invisible Symptoms in MS

The National MS Society
and MS Learn Online present...

A new Feature Presentation:
 
 
Part one of a two-part video webcast series that explores...
 
  • What is an invisible symptom?
  • Can invisible symptoms be managed?
  • Is this an MS symptom?
 
Click here to view the webcast, or copy into your browser: http://www.nationalmssociety.org/multimedia-library/ms-learn-online/index.aspx




***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************

Novartis International AG: Novartis announces Russian regulatory approval for Gilenya®, a once-daily oral multiple sclerosis therapy

Fri Sep 10, 2010 1:16am EDT

Novartis International AG / Novartis announces Russian regulatory approval for Gilenya, a once-daily oral multiple sclerosis therapy and first in a new class processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

 * Russia is first country to approve Gilenya for the treatment of relapsing remitting MS, the most common form of the disease
 * Gilenya is the first disease-modifying treatment in a new drug class and offers significant efficacy with a well-characterized safety tolerability profile
* Action from the US Food and Drug Administration (FDA) on Gilenya is expected in September 2010; other submissions under review worldwide Basel, September 10, 2010- The Russian health authority, the Federal Service on Surveillance in Healthcare and Social Development, has granted approval for Gilenya (fingolimod) 0.5 mg once-daily oral therapy for the treatment of relapsing remitting multiple sclerosis (MS).

Approximately 85% of patients with MS are estimated to have the relapsing remitting form at the onset of disease[1].

Russia is the first country to approve Gilenya, providing a new treatment option offering significant efficacy for patients in the convenience of an oral capsule. Novartis expects to launch Gilenya in Russia in early 2011.

In June, an advisory committee of the US Food and Drug Administration (FDA) unanimously recommended approval of Gilenya and action from the FDA is expected in September 2010. Gilenya is also under review by the European Medicines Agency (EMA) as well as other health authorities worldwide.

Continue reading this Reuter's article by clicking here


***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************

On October 16th, Reap the Savings from Macy's on October 16th (USA only)





On October 16th, 2010 save tens or hundreds of dollars at a Macy's store or online, while at the same time helping to provide a donation to a Not For Profit organization


MS Views and News, Inc., has partnered with Macy’s nationwide (USA) in a Shop for a Cause event. Macy’s has been sponsoring this event since 2006. 


With little effort, a $10.00 donation you can reap the rewards of significant savings at Macy's anywhere in the USA or online. Please contribute only $10.00 to MSV&N (more is always welcome) and in return you will receive a ticket valid for up to 25% off a single item.  



SHOP for a CAUSE - Find THE MAGIC of Giving Back on Saturday October 16th, 2010. It's Fast and Simple. Donate to MS Views and News, Inc., and receive  a Macy's Coupon from 'MS Views and News'  which will allow you to use a WOW coupon that gives you 25% Off on any one item or use the WOW all day pass that gives you 10 & 20%  discounts off many other items.  The coupon will also allow you to ENTER FOR A CHANCE TO WIN A $500.00 Macy's Gift Card.



(Shop for a Cause tickets provide discount savings in most departments all day long. Shop for a Cause is special because you can save on most items throughout the store and online. Additionally you will be entered for an opportunity to win a $500 gift card). 


Your charitable donation to 'MS Views and News' (MSV&N) is tax deductible.


Kindly submit your $10.00 donation and you will be sent your savings coupon by mail.  All Macy’s tickets will be sent after receipt of your contribution. ACT Fast as time is needed for your check to clear, (if paying by check) and for the coupon to be mailed to you.

Please mail your check to: 
MS Views and News, Inc.
8669 SW 51st Street
Cooper City, Fl. 33328-4301

Credit card donations, including Master Card and Visa, are accepted.
This can be done via email, our online Paypal donations link or by calling Stuart Schlossman - President of MS Views and News, Inc. To call Stuart, dial 1-954-684-1683.

When either mailing a check or paying by credit card, be sure to provide us with a mailing address to send your coupon or coupons and please provide an email address and telephone contact number.
 
Feel free to contact Campaign Leader: Jill Molberger (jebmol@aol.comor  Stuart Schlossman (stuart@msviewsandnews.org) with any questions.

Thanking you in advance, for helping our efforts to provide news and information.


Best Regards,
Stuart Schlossman
Stuart Schlossman
President & Founder of MS Views and News, Inc.
Editor of Stu's Views and MS Related News
Unique in what we do. Bridging the gap to all major MS Organizations when
providing Multiple Sclerosis information and resources from our website, daily
via our blog, and weekly by our e-newsletter








****************************************************************

Thursday, September 9, 2010

Ensure Stem Cell Legislation Gets Priority Attention

Federal Focus - Your MS Activism Newsletter from the National MS Society
September 2010

Two weeks ago, a federal judge issued a preliminary injunction halting all federal funding for human embryonic stem cell research (ESCR). This was a huge setback on the achievements that MS Activists have fought hard to attain in our efforts to move us closer to a world free of multiple sclerosis. Fortunately, just today, the DC Court of Appeals sided with the Department of Justice and stopped the preliminary injunction from halting federal funding for human embryonic stem cell research. This ruling is temporary and only in place while the full arguments are heard in the Court of Appeals.  These full arguments could occur later this month. The Director of the National Institutes of Health (NIH), Dr. Francis Collins, indicated emphatically that he views the attempts to block federal funding as a major crisis in science and that delays will cause irreparable damage to critical research being conducted utilizing stem cells.

With the help of MS Activists, Congress twice comfortably passed bi-partisan legislation permitting federal funding of ESCR, but both bills received presidential vetoes. However, in 2009 an Executive Order lifted previous restrictions on federal funding of ESCR and brought new hope to the millions of people living with chronic and debilitating diseases or disabilities.  Click here to see the Society’s historical work with ESCR.

The current judicial proceedings threaten the progress we have made in stem cell research.  Once again, MS Activists must mobilize to ensure that scientists and researchers have the funding and authority they need to explore this promising field of ESCR. 

While legal battles in the court system are underway, the only way to guarantee a permanent solution is to pass bi-partisan legislation. Congress must make it a priority to secure a legislative fix to this situation immediately. There are already bi-partisan efforts underway, but we need broad support to fuel momentum.

Congress will soon be back from its summer recess but will only have a few weeks before it recesses again for the November election. That time between Congressional recesses may be the last opportunity to secure needed action from the 111th Congress.

The National MS Society has made a commitment to pursue promising avenues that will lead to solutions that stop disease progression, restore function, and ultimately prevent future generations from ever receiving an MS diagnosis. This commitment is reflected in our decision to support the conduct of scientifically meritorious medical research, including research using human cells, in accordance with federal, state and local laws, and with adherence to the strictest ethical and procedural guidelines. This decision was not reached without intense scrutiny and discussion among volunteers, people living with MS, ethicists, researchers and scientists, and MS neurologists.
Ultimately, more research is needed to better understand which stem cells, and from what sources, could hold significant promise for repairing damage and restoring function, as well as provide a better understanding of the underlying disease cause.

Click here to email your Members of Congress today and ask them to make stem cell research legislation a priority this session.




***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************